north40000 Thursday, 02/14/19 03:58:15 PM Re: Fred Kadiddlehopper post# 5591 Post # of 5652 If funds become readily available, Fred, I would write Helen directly and suggest becoming a cardiovascular disease treatment company in addition to, or instead of, an oncology company. The links important to any company wishing to license from, partner with, or simply buy Amarin to be a wholly owned independent subsidiary are located in links under my avatar north40000 above, and “my stocks” accessed as above. Helen should be impressed by the facts stated in those links, particularly the facts that 1) more people die from CVDs than from all cancers/tumors combined; 2) the treatment with Vascepa of such CVDs is highly effective nearly across the board, and at a very low cost(I pay $36 for an entire years supply of Vascepa). My own scrip for Vascepa was off- label for the already FDA-approved Vascepa for an indication I never had; my scrip resulted from family history of CVD + Type -1 diabetes that I had since 1957; my personal physician wrote that scrip, off label in 2013 and LabCorp analysis of vials of blood indicate to him that my risk for CVD has been “optimally suppressed” by the dosage of Vascepa I have taken every day since 4/01/2013; 3) the statements by Dr. Bhatt presented Nov. 10 in Chicago + the videos featuring Dr. Bhatt linked above; 4) the prescriptions for Vascepa last week were reported to be all time highs, and are expected to be further all time highs when reported early tomorrow morning(ESTime) on the IHub AMRN message board; 5) NEJM has published the results of Amarin’s Reduce-It clinical trial; first on-line the afternoon of November 10, and again in print version on January 3, 2019. Dr. Bhatt is lead author of that article. 6) Amarin has reported it will file its sNDA on or before the end of March 2019. The indications and label it will seek FDA approval for are unknown to me, but obviously will include the primary and pre-specified secondary indications specified in Reduce-It trial. That’s it for now, Fred. As a SH, it is a suggestion. I expect there may be competition from other companies.